Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Pierre Fabre Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (43)
ARTG (18)
Prescription medicine registration (5)
Australian Public Assessment Report (AusPAR) (1)
Designation or determination (1)

Date

2026 (19)
2025 (16)
2024 (4)
2023 (6)
2022 (9)
2021 (4)
2020 (1)
2019 (3)
2018 (2)
2015 (4)

Search

Sponsor content

68 result(s) found, displaying 51 to 60

JONCIA milnacipran hydrochloride 25 mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

9 June 2022

Cancellation by sponsor

Requested by Pierre Fabre Australia Pty Ltd
Hemangiol-propranolol hydrochloride Cancelled under Section 30(1)(c) of the Act

9 June 2022

Cancellation by sponsor

Requested by Pierre Fabre Australia Pty Ltd
JONCIA milnacipran hydrochloride 100 mg capsule bottle Cancelled under Section 30(1)(c) of the Act

9 June 2022

Cancellation by sponsor

Requested by Pierre Fabre Australia Pty Ltd
Eau Thermale Avene Summer Essentials Cancelled under Section 30(1)(c) of the Act

14 April 2022

Cancellation by sponsor

Requested by Pierre Fabre Australia Pty Ltd
JAVLOR vinflunine ditartrate 250mg/10mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Pierre Fabre Australia Pty Ltd
JAVLOR vinflunine ditartrate 100mg/4mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Pierre Fabre Australia Pty Ltd
JAVLOR vinflunine ditartrate 50mg/2mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Pierre Fabre Australia Pty Ltd
BRAFTOVI (Pierre Fabre Australia Pty Ltd)

13 May 2021

Prescription medicine registration

Active ingredients: encorafenib.
MEKTOVI binimetinib 15 mg film-coated tablet blister pack (295440)

3 January 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for MEKTOVI binimetinib 15 mg film-coated tablet blister pack.
BRAFTOVI encorafenib 75 mg capsule blister pack (295441)

3 January 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for BRAFTOVI encorafenib 75 mg capsule blister pack.

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.